ArticleEuropean journal of nuclear medicine and molecular imaging2020
Article in European journal of nuclear medicine and molecular imaging, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07635524 (A Two Center Phase 2 Trial of 61Cu-noDAGa-PSMA I&T), which is not on this map. Cited by 47 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Two Center Phase 2 Trial of 61Cu-noDAGa-PSMA I&T (61Cu-NU101) for Patients With Prostate Cancer
Who cites it
47 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- The role of PSMA PET/CT in staging patients with intermediate-risk prostate cancer.BJU international · 2026Pooled it
- The Role of Magnetic Resonance Imaging and Positron Emission Tomography/Computed Tomography in the Primary Staging of Newly Diagnosed Prostate Cancer: A Systematic Review of the Literature.European urology oncology · 2021Pooled it
- A prospective head-to-head comparison of [European journal of nuclear medicine and molecular imaging · 2023Trial
- Incremental Impact of [Molecular imaging and biology · 2022Trial
- Pelvic lymph-node staging withEuropean journal of nuclear medicine and molecular imaging · 2021Trial
- A dual-tracer approach for enhanced nodal staging in prostate cancer: the role of [European journal of nuclear medicine and molecular imaging · 2026Article
- Focusing on Prostate-Specific Membrane Antigen in Precision Diagnosis and Treatment of Prostate Cancer.Biomedicines · 2026Review
- Review
- Revolutionizing Prostate Cancer Detection: The Role of Approved PSMA-PET Imaging Agents.Pharmaceuticals (Basel, Switzerland) · 2025Review
- The potential of gallium-68 prostate-specific membrane antigen positron emission tomography/computed tomography as a main diagnostic tool in prostate cancer staging.Central European journal of urology · 2025Review
- PSMA PET/CT in the low- to intermediate-risk prostate cancer: when and why?Asian journal of andrology · 2024Article
- Navigating the evolving diagnostic and therapeutic landscape of low- and intermediate-risk prostate cancer.Asian journal of andrology · 2024Review
- Scalability study on [EJNMMI radiopharmacy and chemistry · 2024Article
- Quantitative PSMA-PET parameters in localized prostate cancer: prognostic and potential predictive value.Radiation oncology (London, England) · 2024Article
- Diagnostic Accuracy of Molecular Imaging Techniques for Detecting Prostate Cancer: A Systematic Review.Diagnostics (Basel, Switzerland) · 2024Review
- "One Method to Label Them All": A Single Fully Automated Protocol for GMP-CompliantCurrent radiopharmaceuticals · 2024Article
- Advancements in PSMA ligand radiolabeling for diagnosis and treatment of prostate cancer: a systematic review.Frontiers in oncology · 2024Review
- [Frontiers in endocrinology · 2024Article
- Comparison of Multiparametric MRI, [Cancers · 2023Article
- Early biochemical and radiographic response after one cycle of [European journal of nuclear medicine and molecular imaging · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThe present study is based on a retrospective analysis of Gallium-68 (
methodsA total of 82 men were included in the study and were imaged with
resultsPSMA-positive disease was detected in 83% of patients with 66/82 (80.5%) primary tumours being visualized. PSMA-avid lymph nodes were recorded in 17/82 patients (20.7%, 3 with intermediate-risk and 14 with high-risk PCa); distant disease was found in 14/82 subjects (17.1%, 2 with intermediate-risk and 12 with high-risk PCa). No extraprostatic disease was found in low-risk PCa. SUV
conclusionsIn patients with initial diagnosis of intermediate- and high-risk prostate cancer,
Indexed as
Identifiers
31529265What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.